 This is kind of exciting. There was just a big meeting of all the cardiologists in Barcelona, and the European Society of Cardiology just put out this huge guideline on algorithms and ways to diagnose cancer therapy and cardio toxicity related to cancer therapies. It's a 133 page document, and it's remarkable with many figures in there. So when you're thinking about a cancer therapy and new target therapy and how to sort of not only manage that therapy that may lead to some form of cardiovascular toxicity, but how do you prevent it? So there's a huge amount of that document that speaks to, we need to do a better job at not just treating these things, but we need to focus our attention as to how to prevent these things. So we know we're treating a patient with an agent that potentially has cardiovascular toxicity. What can we do to prevent it?